Perfluoroalkyl chemicals and chronic kidney disease in US Adults

American Journal of Epidemiology

Volumn 174, Issue 8, 2011, Pages 893-900

  Shankar, Anoop ^a   Xiao, Jie ^a   Ducatman, Alan ^a  

^a WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

fluorocarbons; kidney diseases; nutrition surveys

Indexed keywords

CHOLESTEROL; PERFLUOROOCTANESULFONIC ACID; PERFLUOROOCTANOIC ACID;

ADULT; AGE STRUCTURE; BODY MASS; DIABETES; DISEASE PREVALENCE; ETHNICITY; EXPERIMENTAL STUDY; FILTRATION; HYPERTENSION; MEASUREMENT METHOD; ORGANIC ACID; ORGANIC COMPOUND; POLLUTION EXPOSURE; PUBLIC HEALTH; RISK FACTOR; SURVEY;

ADULT; AGE; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; ENVIRONMENTAL EXPOSURE; ETHNICITY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; RACE DIFFERENCE; SEX DIFFERENCE; SEX RATIO; UNITED STATES;

ADULT; ALKANESULFONIC ACIDS; ENVIRONMENTAL EXPOSURE; FEMALE; FLUOROCARBONS; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NUTRITION SURVEYS; OCTANOIC ACIDS;

UNITED STATES;

ANIMALIA;

EID: 80054064552     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwr171     Document Type: Article

References (41)

1. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 suppl 1): S1-S266.
2. Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67(6):2089-2100. (Pubitemid 41623371)
3. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298(17): 2038-2047. (Pubitemid 350074801)
4. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108(17):2154-2169. (Pubitemid 37337595)
5. Environmental Protection Agency. Perfluorooctanoic Acid (PFOA) and Fluorinated Telomers. Washington, DC: Environmental Protection Agency; 2010. (http://www.epa.gov/oppt/pfoa/). (Accessed May 5, 2010).
6. Lau C, Anitole K, Hodes C, et al. Perfluoroalkyl acids: a review of monitoring and toxicological findings. Toxicol Sci. 2007; 99(2):366-394. (Pubitemid 351753056)
7. Calafat AM, Wong LY, Kuklenyik Z, et al. Polyfluoroalkyl chemicals in the U.S. population: data from the National Health and Nutrition Examination Survey (NHANES) 2003-2004 and comparisons with NHANES 1999-2000. Environ Health Perspect. 2007;115(11):1596-1602.
8. Cui L, Zhou QF, Liao CY, et al. Studies on the toxicological effects of PFOA and PFOS on rats using histological observation and chemical analysis. Arch Environ Contam Toxicol. 2009;56(2):338-349.
9. Olsen GW, Burris JM, Ehresman DJ, et al. Half-life of serum elimination of perfluorooctanesulfonate, perfluorohexanesulfonate, and perfluorooctanoate in retired fluorochemical production workers. Environ Health Perspect. 2007;115(9):1298-1305. (Pubitemid 47471253)
10. Kennedy GL Jr, Butenhoff JL, Olsen GW, et al. The toxicology of perfluorooctanoate. Crit Rev Toxicol. 2004;34(4):351-384. (Pubitemid 38888064)
11. Han X, Kemper RA, Jepson GW. Subcellular distribution and protein binding of perfluorooctanoic acid in rat liver and kidney. Drug Chem Toxicol. 2005;28(2):197-209. (Pubitemid 40559525)
12. Yoo H, Guruge KS, Yamanaka N, et al. Depuration kinetics and tissue disposition of PFOA and PFOS in white leghorn chickens (Gallus gallus) administered by subcutaneous implantation. Ecotoxicol Environ Saf. 2009;72(1):26-36.
13. Butenhoff JL, Kennedy GL Jr, Hinderliter PM, et al. Pharmacokinetics of perfluorooctanoate in cynomolgus monkeys. Toxicol Sci. 2004;82(2):394-406. (Pubitemid 39600066)
14. Qian Y, Ducatman A, Ward R, et al. Perfluorooctane sulfonate (PFOS) induces reactive oxygen species (ROS) production in human microvascular endothelial cells: role in endothelial permeability. J Toxicol Environ Health A. 2010;73(12): 819-836.
15. Hu W, Jones PD, DeCoen W, et al. Alterations in cell membrane properties caused by perfluorinated compounds. Comp Biochem Physiol C Toxicol Pharmacol. 2003;135(1):77-88. (Pubitemid 36644994)
16. Sutton TA, Fisher CJ, Molitoris BA. Microvascular endothelial injury and dysfunction during ischemic acute renal failure. Kidney Int. 2002;62(5):1539-1549. (Pubitemid 35286261)
17. Sutton TA, Mang HE, Campos SB, et al. Injury of the renal microvascular endothelium alters barrier function after ischemia. Am J Physiol Renal Physiol. 2003;285(2):F191-F198. (Pubitemid 36871191)
18. Sutton TA. Alteration of microvascular permeability in acute kidney injury. Microvasc Res. 2009;77(1):4-7.
19. Steenland K, Tinker S, Frisbee S, et al. Association of perfluorooctanoic acid and perfluorooctane sulfonate with serum lipids among adults living near a chemical plant. Am J Epidemiol. 2009;170(10):1268-1278.
20. Nelson JW, Hatch EE, Webster TF. Exposure to polyfluoroalkyl chemicals and cholesterol, body weight, and insulin resistance in the general U.S. population. Environ Health Perspect. 2010;118(2):197-202.
21. Sakr CJ, Kreckmann KH, Green JW, et al. Cross-sectional study of lipids and liver enzymes related to a serum biomarker of exposure (ammonium perfluorooctanoate or APFO) as part of a general health survey in a cohort of occupationally exposed workers. J Occup Environ Med. 2007;49(10): 1086-1096. (Pubitemid 350287341)
22. Sakr CJ, Leonard RC, Kreckmann KH, et al. Longitudinal study of serum lipids and liver enzymes in workers with occupational exposure to ammonium perfluorooctanoate. J Occup Environ Med. 2007;49(8):872-879. (Pubitemid 47254709)
23. Olsen GW, Zobel LR. Assessment of lipid, hepatic, and thyroid parameters with serum perfluorooctanoate (PFOA) concentrations in fluorochemical production workers. Int Arch Occup Environ Health. 2007;81(2):231-246. (Pubitemid 47617455)
24. Muntner P, Coresh J, Smith JC, et al. Plasma lipids and risk of developing renal dysfunction: the Atherosclerosis Risk in Communities Study. Kidney Int. 2000;58(1):293-301. (Pubitemid 30429874)
25. Shankar A, Klein R, Moss SE, et al. The relationship between albuminuria and hypercholesterolemia. J Nephrol. 2004;17(5): 658-665. (Pubitemid 40484578)
26. Lin CY, Chen PC, Lin YC, et al. Association among serum perfluoroalkyl chemicals, glucose homeostasis, and metabolic syndrome in adolescents and adults. Diabetes Care. 2009; 32(4):702-707.
27. Chen J, Muntner P, Hamm LL, et al. Insulin resistance and risk of chronic kidney disease in nondiabetic US adults. J Am Soc Nephrol. 2003;14(2):469-477. (Pubitemid 36150872)
28. Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med. 2004;140(3):167-174.
29. Steenland K, Tinker S, Shankar A, et al. Association of perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) with uric acid among adults with elevated community exposure to PFOA. Environ Health Perspect. 2010;118(2): 229-333.
30. Shankar A, Klein R, Klein BE, et al. The association between serum uric acid level and long-term incidence of hypertension: population-based cohort study. J Hum Hypertens. 2006;20(12):937-945. (Pubitemid 44782827)
31. Obermayr RP, Temml C, Gutjahr G, et al. Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol. 2008;19(12):2407-2413.
32. National Center for Health Statistics. National Health and Nutrition Examination Survey. Hyattsville, MD: National Center for Health Statistics; 2010. (http://www.cdc.gov/nchs/nhanes/nhanes2003-2004/nhanes03-04.htm). (Accessed May 5, 2010).
33. National Center for Health Statistics. National Health and Nutrition Examination Survey: 1999-2000 Data Documentation, Codebook, and Frequencies. Hyattsville, MD: National Center for Health Statistics; 2010. (http://www.cdc.gov/nchs/nhanes/nhanes1999-2000/LAB18.htm). (Accessed April 15, 2011).
34. Selvin E, Manzi J, Stevens LA, et al. Calibration of serum creatinine in the National Health and Nutrition Examination Surveys (NHANES) 1988-1994, 1999-2004. Am J Kidney Dis. 2007;50(6):918-926. (Pubitemid 350122815)
35. National Center for Health Statistics. Laboratory Procedure Manual: Creatinine in Refrigerated Serum: 2003-2004. Hyattsville, MD: National Center for Health Statistics; 2004. (http://www.cdc.gov/nchs/data/nhanes/nhanes-03-04/ l40-c-met-creatinine.pdf). (Accessed May 6, 2010).
36. National Center for Health Statistics. Laboratory Procedure Manual: Creatinine in Refrigerated Serum: 2005-2006. Hyattsville, MD: National Center for Health Statistics; 2006. (http://www.cdc.gov/nchs/data/nhanes/nhanes-05-06/ biopro-d-met-creatinine.pdf). (Accessed April 15, 2011).
37. Myers GL, Miller WG, Coresh J, et al. Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program. Clin Chem. 2006;52(1):5-18. (Pubitemid 43032461)
38. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the Modification of Diet in Renal Disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145(4):247-254. (Pubitemid 46768608)
39. National Health and Nutrition Examination Survey. Laboratory Procedures Manual. Atlanta, GA: Centers for Disease Control and Prevention; 2001. (http://www.cdc.gov/nchs/data/nhanes/lab1-6.pdf). (Accessed April 15, 2010).
40. Chobanian AV, Bakris GL, Black HR, et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206-1252. (Pubitemid 37553153)
41. Frisbee SJ, Brooks AP Jr, Maher A, et al. The C8 Health Project: design, methods, and participants. Environ Health Perspect. 2009;117(12):1873-1882.